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ies from an HIV-1 subtype A-infected donor. Two antibodies recognized
epitopes revealed within the CD4-bound conformation of Env, while
one recognized anepitopewithin theV3 loop of Env. Despite identifying
an anti-V3 antibody capable of mediating ADCC, the anti-V3 speciﬁcity
contributed very little to the ADCC response of the donor's plasma. In-
deed, when the authors introduced mutations abrogating Fc receptor
binding (i.e., LALA mutations) within each of the three monoclonal an-
tibodies and used the mutants to block ADCC triggered by whole plas-antibodies speciﬁc for CD4-induced epitopes and no inhibition by the
Antibodies capable of eliminating HIV-1-infected cells via antibody-
dependent cellular cytotoxicity (ADCC) are present in most HIV-1-
infected individuals. The ability of antibodies to trigger ADCC is associat-
ed with slower progression to AIDS, as well as vaccine-conferred
protection from HIV-1 infection in the RV144 trial (Baum et al., 1996,
Haynes et al., 2012). The RV144 trial enrolled over 16,000 subjects in
Thailand. Half of the subjects were immunized with a prime-boost vac-
cine regimen that, although did not induce signiﬁcant anti-HIV CD8 T
cell or broad neutralizing antibody responses, did induce robust non-
neutralizing antibody responses with ADCC function. Although ADCC
antibodies can target a wide array of epitopes within the HIV-1 enve-
lope (Env), recent studies have demonstrated that epitopes revealed
within Env upon entering the CD4-bound conformation are preferen-
tially targeted by ADCC antibodies within HIV-1-infected individuals
and RV144 vaccinees (Bonsignori et al., 2012, Veillette et al., 2015).
The HIV-1 Env protein binds to the cell-surface molecule CD4 to allow
virion entry and this CD4 binding causes a conformational change in
Env. In the current issue of EBioMedicine, Williams et al. provide further
evidence of preferential targeting of the CD4-bound conformation of
Env by ADCC antibodies in a Kenyan cohort infected with HIV-1
(Williams et al., 2015).
In their manuscript, Williams et al. demonstrate that GFP-tagged
virus-like particles can be employed to identify and sort Env-speciﬁc
B-cells (Williams et al., 2015). These B-cells' heavy and light chain
immunoglobulin genes were sequenced then HIV-1-speciﬁc antibodies
were generated and screened for anti-viral functions, such as ADCC.om.2015.09.001.
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).lma, they observed robust inhibition by the LALA versions of the two
LALA version of the anti-V3 monoclonal antibody. To establish that
CD4-induced epitopes were commonly targeted amongst the Kenyan
cohort of the monoclonal antibody donor, the authors further demon-
strated that LALA versions of the two antibodies speciﬁc for CD4-
induced epitopes robustly inhibited the plasma ADCC of nine additiona
donors. These results are consistentwith previous researchdemonstrat-
ing that ADCC-competent anti-variable loop antibodies are relatively
rare amongst monoclonal antibodies isolated from RV144 vaccinees
(Bonsignori et al., 2012). Further, this is consistent with an absorption
experiment demonstrating that the majority of ADCC antibodies con-
tributing to plasma ADCC responses are not directed to variable loop
epitopes (Veillette et al.. 2015). Collectively, the data from Williams
et al. and others demonstrates that, while some anti-V3 antibodies
may be able to trigger ADCC, these antibodies contribute little to the
capacity of plasma to clear infected cells via ADCC. Further research
into the ability of anti-V3 antibodies to trigger ADCC, however, may
prove fruitful for identifying ADCC antibodies capable of recognizing
HIV-1 Env independently of CD4.
Much evidence points towards a role for Vpu and Nef in the evasion
of ADCC responses by HIV-1-infected cells (Veillette et al.. 2014). Both
Vpu and Nef downregulate cell surface CD4 and prevent Env from
entering the CD4-bound conformation prominently targeted by ADCC
antibodies (Veillette et al., 2014, Veillette et al., 2015). Vpu also
downregulates cellular expression of tetherin, a protein involved in
keeping HIV-1 virions at the cell surface and thus increasing epitope
availability (Van Damme et al., 2008). Additionally, motifs within the
membrane proximal region of Env serve to limit Env expression on
the surface of infected cells (Von Bredow et al., 2015).
The Vpu and Nef-mediated down regulation of CD4 at ﬁrst blush ap-
pears paradoxical to the notion that ADCC antibodies targeting the CD4-
1299M.S. Parsons, S.J. Kent / EBioMedicine 2 (2015) 1298–1299bound conformation of Env protect from HIV-1 infection. In their study,
Williams et al. demonstrated that their twomonoclonal antibodies spe-
ciﬁc for CD4-induced epitopes can inhibit HIV-1 replication in a CD4+T
cell line, CEM.NKr-CCR5 (Williams et al., 2015). These data demon-
strate that these monoclonal antibodies can target the Env of the uti-
lized isolate as it naturally appears on the surface of infected cells.
Questions remain, however, about the competency of the Nef and Vpu
of the viral isolate utilized, as well as the extent of CD4 downregulation
on CEM.NKr-CCR5 cells infected with the viral isolate. An important re-
search priority in this ﬁeld is to identify epitopes and mechanisms
whereby ADCC antibodies can target HIV-infected cells for elimination,
regardless of viral Env conformation.
There is much hope that the mechanism of ADCC can, beyond the
31% efﬁcacy of the RV144 trial, be exploited for prevention of HIV-1 in-
fection through vaccination (Wren et al., 2013). Further, ADCC may as-
sist in effort to develop a cure for HIV-1 infection through eliminating
reactivated latently infected cells, since reactivating latently infected
cells alone, without immune clearance, may be insufﬁcient (Lee et al.,
2015, Wren et al., 2013). To realize these goals there is likely a need to
identify and utilize ADCC antibodies capable of recognizing non-CD4-
bound Env epitopes, such as epitopes within V3, which would allow
for the elimination of latent viruses or transmitted/founder viruses
that fully or sufﬁciently downregulate CD4 and render ADCC antibodies
targeting CD4-induced epitopes non-functional. A major caveat of
targeting the V3 region is the high diversity in this region between
viruses. Importantly, Williams et al. provide proof of principle that
epitopes present on Env not bound to CD4 can be targeted for ADCC
by antibodies speciﬁc for CD4-independent epitopes (Williams et al.,
2015).
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